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Abstract
Cancer poses a massive health burden with incidence rates expected to double globally over the
next decade. In the United Kingdom screening programmes exists for cervical, breast, and
colorectal cancer. The ability to screen individuals for solid malignant tumours using only a
peripheral blood sample would revolutionise cancer services and permit early diagnosis and
intervention. Raman spectroscopy interrogates native biochemistry through the interaction of light
with matter, producing a high definition biochemical 'fingerprint' of the target material. This paper
explores the possibility of using Raman spectroscopy to discriminate between cancer and non-
cancer patients through a peripheral blood sample. Forty blood samples were obtained from
patients with Head and Neck cancer and patients with respiratory illnesses to act as a positive
control. Raman spectroscopy was carried out on all samples with the resulting spectra being used
to build a classifier in order to distinguish between the cancer and respiratory patients' spectra;
firstly using principal component analysis (PCA)/linear discriminant analysis (LDA), and secondly
with a genetic evolutionary algorithm. The PCA/LDA classifier gave a 65% sensitivity and specificity
for discrimination between the cancer and respiratory groups. A sensitivity score of 75% with a
specificity of 75% was achieved with a 'trained' evolutionary algorithm. In conclusion this
preliminary study has demonstrated the feasibility of using Raman spectroscopy in cancer screening
and diagnostics of solid tumours through a peripheral blood sample. Further work needs to be
carried out for this technique to be implemented in the clinical setting.
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Introduction
Cancer poses a massive health burden with incidence
rates expected to double globally over the next decade[1].
In the United Kingdom screening programmes exist for
cervical, breast and colorectal cancer with the premise that
early detection affords early intervention with improved
chance of cure. Screening programmes at present target a
cancer within an asymptomatic sub-group of the popula-
tion deemed to be at greater risk of suffering the disease.
The potential to screen patients in the community
through a peripheral blood sample for any solid malig-
nant tumour would revolutionise cancer services. Patients
with a positive result could then be referred for further
investigation; whilst a negative result would allay anxiety
and reduce the need for further expensive investigations
with possible associated morbidity.
Previous work has investigated plasma and serum levels
of deoxyribonucleic acid (DNA), and ribonucleic acid
(RNA) in attempts to detect the presence of cancer [2-5].
It has been reported that serum and plasma samples from
cancer patients generally have higher concentrations of
these nucleic acids compared with control samples. The
origin of the increased levels has not yet been fully eluci-
dated but is thought to be due to a variety of different
mechanisms including; apoptosis, tumour necrosis, and
possibly active release. However, a large European, multi-
centred, randomised controlled trial, utilising samples
from patients with various types of cancer, healthy con-
trols and patients with chronic obstructive pulmonary dis-
ease concluded plasma concentrations of DNA were
neither sensitive nor specific enough for cancer diagnos-
tics or screening purposes[6].
Fluorescence spectroscopy has also been used for poten-
tial cancer detection in blood samples [7]. These experi-
ments suggested that differences between cancer and non-
cancer cohorts may arise due to the modification of fluor-
ophores by tumour associated metabolites, changes in
protein composition, and possible changes to the envi-
ronment of the fluorophores thus altering their physico-
chemical properties. As yet fluorescence spectroscopy has
not been applied to the clinical setting in cancer detection.
This highlights the need for a sensitive biochemical anal-
ysis where changes in the biochemical composition of
blood products can be detected. It may then be possible to
detect the presence of cancer in an individual whether due
to the presence of abnormal molecules; increased levels of
naturally occurring biochemical products; or changes in
native biochemistry secondary to tumour formation.
Raman spectroscopy relies on the scattering of photons
when incident light interacts with the target matter. The
molecular interactions cause a frequency shift that reflects
the energy of particular molecular vibrations. These vibra-
tions are molecular bond specific allowing a 'biochemical
fingerprint' to be constructed of the material. Any physio-
logical change or pathological process that results in
changes to the native biochemistry would therefore lead
to changes in Raman spectra. These spectra are highly
detailed allowing subtle differences in biochemistry to be
identified. This technique has received much attention in
tissue diagnostic possibilities but there is a paucity of lit-
erature in its application to cancer diagnosis through a
peripheral blood sample [8-11].
Raman spectra of biochemical compounds produce high
dimensional multivariate datasets; in order to 'unlock'
this data to detect subtle differences between cohorts it is
paramount that the analysis is performed by equally
sophisticated techniques. Multivariate statistical methods
such as Principal Component Analysis (PCA) and Linear
Discriminant Analysis (LDA) are generally accepted for
use in the classification of Raman spectra[12,13]. PCA
transforms the data into a subspace in which the major
modes of variation are captured as a linear combination
of the original input. LDA is a straightforward classifica-
tion scheme which rather than reducing the dimensional-
ity of the data based on how it varies, aims to efficiently
select the linear combination of the input that best dis-
criminates classification of each example to its corre-
sponding label e.g. Cancer/Non-cancer. Along with
conventional techniques a more novel approach of using
genetic evolutionary programming to evolve a classifier
was used in this study. This pattern recognition technique
combines rules and features in order to evolve a classifier.
Whether based upon the detection of cancer products or
the body's response to the disease process the advantage
of cancer screening through a peripheral blood sample is
clear. The aim of this preliminary study was to identify
whether Raman spectroscopy coupled with sophisticated
data analysis techniques could discriminate between
peripheral blood samples from patients with and without
cancer.
Materials and methods
Patient samples
All patients participating in this study did so with their full
informed consent. Peripheral blood samples were
obtained from 20 patients attending the Leeds Head and
Neck multidisciplinary clinic. All patients were new refer-
rals to the clinic, although this would also include
patients who had previously undergone resection of can-
cer and had re-presented with recurrence. Patients had
tumours from the head and neck; tongue, larynx, skin,
and salivary glands. The tumours were of various type,
grade and stage.Head & Neck Oncology 2009, 1:34 http://www.headandneckoncology.org/content/1/1/34
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Control samples were obtained from patients attending
the Leeds Chest Clinic. These patients suffered a range of
respiratory diseases including asthma, chronic obstructive
pulmonary disease (COPD), and bronchiectasis. Patients
with a history of cancer or ongoing treatment for cancer
were excluded from the study.
Ethics
Ethical opinion was sought and granted from Leeds West
ethical committee. Ref: 06/Q1205/226.
2 blood samples were collected from each patient in spe-
cialist blood tubes containing 3.2% sodium citrate. Sam-
ples were centrifuged immediately at 3000 rpm for
approximately 10 minutes. The supernatant (plasma) was
removed and split into 4 cryovials. These vials were placed
in a -80°C freezer for storage until use.
Raman spectroscopy
The Raman spectra were obtained from all samples using
a Renishaw 'System 1000' Raman microscope. Excitation
was provided by a Sacher Lasertechnik Littrow external
cavity laser set at 783 nm. Detection of the Raman scat-
tered light was via a Renishaw RenCam NIR enhanced
thermoelectrically cooled CCD camera. The spectrometer
was coupled to a Leica DMLM microscope; and the excit-
ing light is delivered to the sample, and the scattered light
collected from the sample, via a 50 times Leica micro-
scope objective. The spectrometer used holographic notch
filters to remove Rayleigh scattered light from the col-
lected light. The Raman scattered light was then dispersed
across the CCD array detector by a single stage, 250 mm
focal length grating spectrometer. The microscope was
equipped with a motorised XYZ positioning stage (Prior)
with integrated position sensors on the X and Y axes (Ren-
ishaw). Instrument control and data collection were per-
formed with Renishaw WiRE software which operates
within Galactic GRAMS software.
Raman measurements
Individual samples were each thawed and pipetted onto a
quartz microscope slide. This was allowed to air dry
before Raman spectroscopy measurements were taken. An
extended spectrum reading from 600 - 1800 nm was
recorded. The time to acquire the spectral reading was 20
seconds for all samples. The microscope lens was a 50
times air objective with a 0.75 numerical aperture. Ten
spectra were obtained from each plasma sample. The 10
spectra could then be converted to a mean spectrum for
each sample. The plasma samples for the cancer and non-
cancer patients were run alternate so as to rule out any
possible influence of time of day and machine variability.
Data normalisation
The intensity of each Raman spectrum not only depends
on sample characteristics but also on operating equip-
ment. The equipment currently used was un-calibrated as
an experimental calibration protocol has yet to be
devised. The raw data was normalised in order to compare
data across samples as follows;
￿ The data was re-sampled so that the measurements
all correspond to the same Raman shift points (601,
602,,1800) by interpolation between the closest
points.
￿ Each spectra is normalised so that the area under the
curve between a Raman shift of x = 700 and 1400 is
equal. The normalisation factor is based just on this
section as much greater variations arise in spectra out-
side of this range; however the same multiplicative fac-
tor was used on the entire spectrum for each sample.
The normalisation process appeared to align the spec-
tra intensities well. The actual area under the whole
curve varied between 1.6 and 1.9.
￿ The data was smoothed with a Gaussian window
function (a weighted linear filter) to smooth out some
of the noise effects. The weights used were [0.0146
0.0831 0.2356 0.3333 0.2356 0.0831 0.0146 ]. Due to
the measurement techniques used, we expected the
spectra to be locally smooth, and this procedure
helped to reduce the measurement noise seen in the
data.
￿ A mean spectra for each patient is then produced
which can be used for the analysis.
Classification
Raman spectra are high-dimensional data sets. Each spec-
tra contains 1200 Raman shift intensities. We wanted to
be able to distinguish between cancer and non-cancer
(respiratory) samples, from the mean spectra for each
patient. Often it is useful to reduce the dimensionality of
the data, and here we considered 3 ways of doing this: (1)
by choosing the 25 best features from the 1200 data
points using a two sample t-test to identify good features
for the binary classification task, (2) using principal com-
ponent analysis (PCA), to map the data to a lower dimen-
sional space, here with 25 components, and (3) using a
combination of the two, first choosing the 100 best fea-
tures, and then PCA to reduce to 25. For discrimination
between cancer and non-cancer cohorts LDA was per-
formed on the reduced spectra. To evaluate performance,
ten-fold cross-validation was performed, 100 times and
an average performance calculated to avoid bias in the
partition.
Genetic algorithm
The mean spectra were provided as input sequences to the
Implicit Context Representation Cartesian Genetic Pro-
gramming algorithm (IRCGP)[14,15]. IRCGP uses evolu-Head & Neck Oncology 2009, 1:34 http://www.headandneckoncology.org/content/1/1/34
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tionary computing methodology to learn classifiers that
are capable of distinguishing between data classes.
Induced classifiers take the form of programmatic expres-
sions applied to particular offsets within the input data
sequences. These expressions are composed from a set of
simple mathematical functions. Both the choice and con-
nectivity of the functions, and the choice of offsets used
within the input sequences, are determined by the algo-
rithm's evolutionary process. The input sequences were
divided equally into training and test sets. To prevent
over-learning, training of the classifiers was stopped once
classification accuracy of the test sequences started to fall.
Results
All cancer patients agreed to be in the study. The mean age
was 64.7 years, with 12 patients being male and 8 female.
Twenty-one patients were recruited for the control group,
1 patient declined due to being on renal dialysis later that
day and therefore 20 patients were used. The mean age for
the control patients was 66.8 years, with 11 males and 9
females. Table 1 depicts the cancer types the patients of
patients in this study. Table 2 depicts the illnesses the res-
piratory patients were suffering from.
The raw spectra show some variation in intensity levels
(Figure 1), and the normalisation procedure outlined
appeared to create well aligned spectra for each individual
(Figure 2).
Figures 3 and 4 illustrate the graphical representation of
mean Raman spectra for the 20 respiratory and the 20 can-
cer patients respectively. As can be seen the spectra are
similar within each cohort and also between the cohorts.
Figure 5 demonstrates just how similar the two sets of
spectra are for the cancer and non-cancer (respiratory)
groups.
An example set of ten Raman spectra obtained from the  plasma sample of a patient with cancer Figure 1
An example set of ten Raman spectra obtained from 
the plasma sample of a patient with cancer. The x-axis 
depicts the shift in wavelength (Raman shift) from the inci-
dent light.
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Table 1: The cancer types present in this study.
Type of Cancer Number of patients Lymph node involvement
Squamous cell carcinoma 15 8
Malignant melanoma 1 1
Basal cell carcinoma 1 0
Unknown primary 1 1
Merkel cell tumour 1 1
Mucoepidermoid 1 0
Table 2: The respiratory disease in the control group of this 
study.
Respiratory illness Number of patients
COPD and asthma 1
COPD alone 11
Asthma alone 4
Bronchiectasis with Kartagener's syndrome 1
Bronchiectasis 1
Bronchiectasis and asthma 1
Pulmonary fibrosis 1Head & Neck Oncology 2009, 1:34 http://www.headandneckoncology.org/content/1/1/34
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Classification results for the four classification schemes
used to classify the cancer and respiratory data are shown
in Table 3. Conventional LDA approaches showed an
accuracy of around 65% in the average of 100 runs of 10-
fold cross validation. The best performance was 75% sen-
sitivity and 75% specificity by the genetic evolutionary
algorithm which obtained an accuracy of 83%. The result
shown is from a single 10-fold cross validation, and the
increase in performance is due to the way the learned rules
combine various features in a non-linear way to predict
the class labels. As an extra test, when the spectra were ran-
domly assigned to Cancer/Non-Cancer labels, all the clas-
sifiers performed no better than random, adding support
to the fact that we can distinguish between the cancer and
non-cancer samples.
Figure 6 illustrates a receiver operating characteristic curve
(ROC curve). This depicts the sensitivity versus 1 - the spe-
cificity. For the evolutionary algorithm used it can be seen
that the most accurate algorithm produced 75% sensitiv-
ity with 75% specificity on the test data.
Discussion
Respiratory patients were used as a control group for this
study due to their similar ages, sex distribution and life-
style risk factors, and also because of their co-morbid
state. We therefore hoped to eliminate any differences
between the cohorts as being due to the body's common
response to a disease process.
We have demonstrated that using Raman spectroscopy
and LDA analysis yields approximately 65% sensitivity
and specificity for discrimination for cancer and non-can-
cer in peripheral blood samples. However, when the
genetic programme was applied to the data, this increased
sensitivity to 75% with 75% specificity.
In a similar study to ours Pichardo-Molina et al used
Raman spectroscopy to compare serum samples from
breast cancer patients and non-cancer patients [16]. They
recruited 11 cancer patients (4 had metastatic disease) and
12 healthy controls to the study. Initially PCA was used to
define wavelength differences between the 2 cohorts and
ultimately to determine where differences were occurring
The 20 mean spectra for the cancer patients Figure 4
The 20 mean spectra for the cancer patients.
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An example set of ten Raman spectra from the plasma sam- ple of a cancer patient after the data (figure 1) had undergone  the normalisation process Figure 2
An example set of ten Raman spectra from the 
plasma sample of a cancer patient after the data (fig-
ure 1) had undergone the normalisation process.
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The 20 mean spectra for the respiratory patients (non-can- cer) Figure 3
The 20 mean spectra for the respiratory patients 
(non-cancer).
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in the native biochemistry. This latter proved to be unsuc-
cessful due to the complex Raman 'fingerprint' and the
multiple possible origins of peaks within the spectra. The
authors achieved a 90% sensitivity utilizing LDA of the
PCA scores and concluded that differences in Raman spec-
tra were related to beta-carotene levels (peaks around
1155 and 1523); with generally lower values in the cancer
cohort. Similar findings were reported by Li et al.2001
using a Raman system with incident wavelengths of 488
nm and 514.5 nm [17]. A large training set of 1022 sam-
ples containing various malignancies, healthy controls
and other diseases was used, followed by 432 test sam-
ples. Results demonstrated between 70 and 100 per cent
accuracies between cancer, non-cancer, and other illness
groups, although their blood samples were stored at 4°C
for up to 4 days making sample degradation a possible
problem; especially if differing cohorts were run at differ-
ent time points. In our study, LDA also highlighted differ-
ences in the Raman spectra at the 1150 region. The
evolutionary algorithm discovered differences in between
the cancer and non-cancer (respiratory) groups in the
1000 region of the spectra. This region is dominated by
the phenylalanine band and may represent changes in the
native state of this compound in the presence of cancer. It
must be remembered that whilst compounds exhibit
strong signals in certain regions of the spectra, they have
many other peaks making determination of underlying
biochemistry complex.
In a review of the accuracy of the conventional papanico-
laou cervical smear test, Nanda and colleagues found sen-
sitivity to vary between 30 to 87% and specificity from 86
to 100% [18]. Breast cancer screening is undertaken
through 3 yearly mammography; Houssami and col-
leagues (2003) found approximate sensitivity for mam-
mography to be 75% and specificity 88% [19]. Faecal
occult blood testing has recently been introduced in the
UK for individuals over 50 years of age. There is a large
variation in sensitivity (12 to 82%) according to the
region of the bowel affected; specificity is recorded at
approximately 95% [20]. The sensitivity of our test in the
current study is broadly similar to that of established
screening programmes. The import factor is that specifi-
city needs to be very high so no cancers are missed. The
use of the ROC curve in this work allows a 'sliding scale'
approach where increased sensitivity is matched by a
decrease in specificity and vice versa, allowing a 'decision
threshold' to be set.
There are limitations to our study especially the sample
size which makes extrapolation onto populations diffi-
cult. This study was set out as a pilot project; head and
neck patients were chosen yet the malignancies chosen
were not only squamous cell carcinoma (90% of head and
neck cancers). The next trial this group will undertake is to
discriminate between malignancies (gastrointestinal,
breast, etc) as well as a non-cancer cohort. Further work
would then need to categorize patients regarding tumour
load and spread. Patients used in these trails would need
to be followed up after measurements have finished espe-
cially in the non-cancer group; as this may contain indi-
viduals with undiagnosed cancer or pre-malignant
Table 3: The results obtained for the various classifier systems in discriminating between the cancer and non-cancer (respiratory) 
samples.
Classifier Method Accuracy (%) Sensitivity (%) Specificity (%)
LDA on the best 25 features from the t-test 57.9 55.6 60.0
PCA-LDA (LDA on 25 principal components) 65.0 64.7 65.3
100 best > PCA 25 > LDA 65.8 64.9 66.7
Genetic Evolutionary Algorithm 83 75 75
Comparison of the means and range of cancer and respira- tory (non-cancer) spectra Figure 5
Comparison of the means and range of cancer and 
respiratory (non-cancer) spectra.
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changes yet to be recorded. In this event what may seem
erroneous results may well be accurate.
The ultimate aim is to be able to distinguish between can-
cers in the clinic setting; in this study the groups were
quite coarse representations but the initial study was to
solely to discriminate cancer from non-cancer using this
methodology.
It may well prove to be the case that Raman spectroscopy
could diagnose solid tumours from a peripheral blood
sample in the future; however, a more feasible prospect is
the ability to screen individuals at risk of cancer. Com-
pared to cervical screening which is invasive, mammogra-
phy which is undertaken in hospital, Raman blood
analysis could be achieved at the local surgery. Along with
screening, this test could be used as a diagnostic adjunct
for those who attend the general practitioner with symp-
toms suggestive of malignant disease.
Conclusion
This preliminary study has demonstrated the possible fea-
sibility of using Raman spectroscopy in cancer screening
and diagnostics of solid tumours through a peripheral
blood sample. Further work needs to be carried out for
this technique to be implemented in the clinical setting.
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